{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Brimonidine+tartrate+0.025%25",
    "query": {
      "intervention": "Brimonidine tartrate 0.025%"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Brimonidine+tartrate+0.025%25&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T15:26:32.505Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05591755",
      "title": "Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Seasonal Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Ketotifen fumarate ophthalmic solution 0.035%",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine tartrate ophthalmic solution 0.025%",
          "type": "DRUG"
        },
        {
          "name": "Experimental: Vehicle ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 229,
      "start_date": "2022-11-18",
      "completion_date": "2023-08-09",
      "has_results": true,
      "last_update_posted_date": "2025-07-01",
      "last_synced_at": "2026-10-09T15:26:32.505Z",
      "location_count": 6,
      "location_summary": "Louisville, Kentucky • Andover, Massachusetts • Goodlettsville, Tennessee + 3 more",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Goodlettsville",
          "state": "Tennessee"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Falls Church",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05591755"
    },
    {
      "nct_id": "NCT01275105",
      "title": "A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Vehicle",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine Tartrate 0.01%",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine Tartrate 0.025%",
          "type": "DRUG"
        },
        {
          "name": "Oxymetazoline HCl 0.025%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eye Therapies, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2011-01",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-06",
      "last_synced_at": "2026-10-09T15:26:32.505Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01275105"
    },
    {
      "nct_id": "NCT07209410",
      "title": "Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Brimonidine Tartrate Ophthalmic 0.025%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 35,
      "start_date": "2025-11-01",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-10-09T15:26:32.505Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07209410"
    },
    {
      "nct_id": "NCT01675609",
      "title": "Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ocular Redness"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine tartrate 0.025%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eye Therapies, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2012-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-07-31",
      "last_synced_at": "2026-10-09T15:26:32.505Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01675609"
    },
    {
      "nct_id": "NCT05579730",
      "title": "Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine Tartrate 0.025%",
          "type": "DRUG"
        },
        {
          "name": "Ketotifen Fumarate 0.035%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 188,
      "start_date": "2022-10-12",
      "completion_date": "2023-07-22",
      "has_results": true,
      "last_update_posted_date": "2025-02-14",
      "last_synced_at": "2026-10-09T15:26:32.505Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Andover, Massachusetts • Memphis, Tennessee + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Lynchburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05579730"
    },
    {
      "nct_id": "NCT02039765",
      "title": "Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperemia"
      ],
      "interventions": [
        {
          "name": "Brimonidine tartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-02",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2017-04-28",
      "last_synced_at": "2026-10-09T15:26:32.505Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02039765"
    },
    {
      "nct_id": "NCT04007276",
      "title": "The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Glaucoma, Open-Angle",
        "Glaucoma; Drugs",
        "Droopy Eyelid",
        "Ptosis",
        "Glaucoma, Primary Open Angle"
      ],
      "interventions": [
        {
          "name": "brimonidine tartrate ophthalmic solution 0.025%",
          "type": "DRUG"
        },
        {
          "name": "sterile balanced saline solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Tulane University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-11-10",
      "completion_date": "2036-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-01",
      "last_synced_at": "2026-10-09T15:26:32.505Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04007276"
    },
    {
      "nct_id": "NCT01687426",
      "title": "Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glaucoma and Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Brimonidine Tartrate 0.025%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eye Therapies, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2012-09",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2012-12-25",
      "last_synced_at": "2026-10-09T15:26:32.505Z",
      "location_count": 1,
      "location_summary": "Winchester, Massachusetts",
      "locations": [
        {
          "city": "Winchester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01687426"
    },
    {
      "nct_id": "NCT05815758",
      "title": "Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 512,
      "start_date": "2023-04-20",
      "completion_date": "2023-09-18",
      "has_results": true,
      "last_update_posted_date": "2025-07-10",
      "last_synced_at": "2026-10-09T15:26:32.505Z",
      "location_count": 7,
      "location_summary": "Chandler, Arizona • Havre de Grace, Maryland • Andover, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Havre de Grace",
          "state": "Maryland"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Apex",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05815758"
    },
    {
      "nct_id": "NCT05360784",
      "title": "\"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness\"",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Redness"
      ],
      "interventions": [
        {
          "name": "Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation",
          "type": "DRUG"
        },
        {
          "name": "Lumify® (brimonidine tartrate ophthalmic solution 0.025%)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 380,
      "start_date": "2022-05-13",
      "completion_date": "2022-11-23",
      "has_results": true,
      "last_update_posted_date": "2024-08-26",
      "last_synced_at": "2026-10-09T15:26:32.505Z",
      "location_count": 6,
      "location_summary": "Colorado Springs, Colorado • Louisville, Kentucky • Andover, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Shelby",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05360784"
    }
  ]
}